Cite
HARVARD Citation
Schiff, M. et al. (2015). Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. RMD open. 1 (1), p. . [Online].